Special Issue

Topic: Research Progress on Drug Resistance in Acute Myeloid Leukemia

A Special Issue of Cancer Drug Resistance

ISSN 2578-532X (Online)

Submission deadline: 31 Jul 2022

Guest Editor(s)

Dr. Giovanni Martinelli
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.
Dr. Claudio Cerchione
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.

Special Issue Introduction

Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease. It is a relatively rare disease (3-4/100000 in EU), but with a high mortality rate, and more common in older adults (≥ 60 years). Despite advances in its molecular and genomic understanding, prognosis of most patients remains dismal, particularly in elderly people, which represent over 50% of new cases. Standard of care with curative purposes includes intensive chemotherapy +/- allogeneic stem cell transplantation. In the past few years, the therapeutic landscape of AML has rapidly progressed, driven mainly by its genomic characterization, and changed substantially since 2017 to include 8 new FDA-approved targeted agents: midostaurin (FLT3-inihibitor), gilteritinib (FLT3-inihibitor), enasidenib (IDH2-inihibitor), ivosidenib (IDH1-inihibitor), venetoclax (BCL2-inihibitor), gemtuzumab ozogamycin (anti-CD33-drug conjugate), glasdegib (hedgehog pathway-inhibitor), and a liposomal formulation of daunorubicin and cytarabine (CPX-351).

These different novel targeted drugs are improving the outcomes and paving the way for new poly-drug combinations, often including hypomethylating agents (HMA), more specific and less toxic than conventional chemotherapy.

Multiple molecular mechanisms have been implicated for the emergence of multi-drug resistance in AML and several new treatment strategies have been developed against druggable molecular targets to overcome such drug resistance.

The primary purpose of this Special Issue on is to collect new and transformative information regarding new insights about the mechanisms of drug resistance in AML and the role of the tumor micro-environment in treatment failures.

We are particularly interested in papers on precision medicines with a well-defined and preferably unique mechanism of action that show a high clinical impact potential. Manuscripts detailing proof of concept studies in clinical settings are particularly welcome .

In this view, we solicit the participation of Researchers active in the area of clinical, translational studies, basic biology research, pharmacology and drug discovery.

This topic collection will further advance our understanding of leukemia maintenance, progression, treatment and development of resistance. Moreover, it will be of help in developing novel strategies based on precision medicine to treat leukemia in order to achieve higher cure rates.

Accepted article types: Case Report, Clinical Trial, General Commentary, Hypothesis and Theory, Mini Review, Original Research, Perspective, Review, and Systematic Review.

Submission Deadline

31 Jul 2022

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr
Submission Deadline: 31 Jul 2022
Contacts: Chloe Yang, Assistant Editor, chloe@cdrjournal.com

Published Articles

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia

Open Access Review DOI: 10.20517/cdr.2023.12 16 Aug 2023
Views: Downloads:
Download PDF

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

Open Access Review DOI: 10.20517/cdr.2022.130 27 Apr 2023
Views: Downloads:
Download PDF

Targeting regulated cell death pathways in acute myeloid leukemia

Open Access Review DOI: 10.20517/cdr.2022.108 14 Mar 2023
Views: Downloads:
Download PDF

Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment

Open Access Review DOI: 10.20517/cdr.2022.133 13 Mar 2023
Views: Downloads:
Download PDF

Venetoclax resistance: mechanistic insights and future strategies

Open Access Review DOI: 10.20517/cdr.2021.125 5 May 2022
Views: Downloads:
Download PDF

Lysosome-mediated chemoresistance in acute myeloid leukemia

Open Access Review DOI: 10.20517/cdr.2021.122 13 Mar 2022
Views: Downloads:
Download PDF
Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/